Company intelligence / Profile preview

Advanced Proteome Therapeutics Corporation

Burnaby, British Columbia, Canadaadvancedproteome.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Advanced Proteome Therapeutics has developed a proprietary platform for site-selective modification of antibodies to create next-generation ADCs. Their approach aims for higher specificity and lower toxicity compared to traditional chemotherapies. The technology has shown encouraging preclinical results in collaboration with the National Research Council of Canada, supporting efficient and targeted drug delivery to tumors while sparing healthy tissue. No published clinical trial results as of now

Therapeutic areas: Oncology
Modalities: Antibody-drug conjugates (ADCs)protein therapeutics
Industry: Biotech

Drug pipeline

1 asset

Annexin V-128 dimer

Pre-clinical

Indications: Cancer

Partnerships

National Research Council of Canada (NRC) – R&D collaboration on ADC development funded by NRC IRAP program

Beyond the preview

Go deeper on Advanced Proteome Therapeutics Corporation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Advanced Proteome Therapeutics Corporation.

Explore the full profile